139 related articles for article (PubMed ID: 8687433)
1. Potential sites for processing of the human invariant chain by cathepsins D and E.
Kageyama T; Yonezawa S; Ichinose M; Miki K; Moriyama A
Biochem Biophys Res Commun; 1996 Jun; 223(3):549-53. PubMed ID: 8687433
[TBL] [Abstract][Full Text] [Related]
2. Natural processing sites for human cathepsin E and cathepsin D in tetanus toxin: implications for T cell epitope generation.
Hewitt EW; Treumann A; Morrice N; Tatnell PJ; Kay J; Watts C
J Immunol; 1997 Nov; 159(10):4693-9. PubMed ID: 9366392
[TBL] [Abstract][Full Text] [Related]
3. Class II-associated invariant chain peptide-independent binding of invariant chain to class II MHC molecules.
Thayer WP; Ignatowicz L; Weber DA; Jensen PE
J Immunol; 1999 Feb; 162(3):1502-9. PubMed ID: 9973407
[TBL] [Abstract][Full Text] [Related]
4. Specificity of human cathepsin S determined by processing of peptide substrates and MHC class II-associated invariant chain.
Rückrich T; Brandenburg J; Cansier A; Müller M; Stevanović S; Schilling K; Wiederanders B; Beck A; Melms A; Reich M; Driessen C; Kalbacher H
Biol Chem; 2006; 387(10-11):1503-11. PubMed ID: 17081125
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory fragment from the p41 form of invariant chain can regulate activity of cysteine cathepsins in antigen presentation.
Mihelic M; Dobersek A; Guncar G; Turk D
J Biol Chem; 2008 May; 283(21):14453-60. PubMed ID: 18362148
[TBL] [Abstract][Full Text] [Related]
6. Invariant chain can bind MHC class II at a site other than the peptide binding groove.
Wilson NA; Wolf P; Ploegh H; Ignatowicz L; Kappler J; Marrack P
J Immunol; 1998 Nov; 161(9):4777-84. PubMed ID: 9794409
[TBL] [Abstract][Full Text] [Related]
7. A role for the transmembrane domain in the trimerization of the MHC class II-associated invariant chain.
Ashman JB; Miller J
J Immunol; 1999 Sep; 163(5):2704-12. PubMed ID: 10453012
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and NMR structure of p41icf, a potent inhibitor of human cathepsin L.
Chiva C; Barthe P; Codina A; Gairí M; Molina F; Granier C; Pugnière M; Inui T; Nishio H; Nishiuchi Y; Kimura T; Sakakibara S; Albericio F; Giralt E
J Am Chem Soc; 2003 Feb; 125(6):1508-17. PubMed ID: 12568610
[TBL] [Abstract][Full Text] [Related]
9. Studies on activities of invariant chain peptides on releasing or exchanging of antigenic peptides at human leukocyte antigen-DR1.
Xu M; Jackson R; Adams S; Humphreys RE
Arzneimittelforschung; 1999 Sep; 49(9):791-9. PubMed ID: 10514908
[TBL] [Abstract][Full Text] [Related]
10. Cutting edge: a single, essential hydrogen bond controls the stability of peptide-MHC class II complexes.
McFarland BJ; Beeson C; Sant AJ
J Immunol; 1999 Oct; 163(7):3567-71. PubMed ID: 10490947
[TBL] [Abstract][Full Text] [Related]
11. The proteolytic environment involved in MHC class II-restricted antigen presentation can be modulated by the p41 form of invariant chain.
Fineschi B; Sakaguchi K; Appella E; Miller J
J Immunol; 1996 Oct; 157(8):3211-5. PubMed ID: 8871612
[TBL] [Abstract][Full Text] [Related]
12. CLIP-region mediated interaction of Invariant chain with MHC class I molecules.
Powis SJ
FEBS Lett; 2006 May; 580(13):3112-6. PubMed ID: 16678175
[TBL] [Abstract][Full Text] [Related]
13. Substrate specificity of cathepsins D and E determined by N-terminal and C-terminal sequencing of peptide pools.
Arnold D; Keilholz W; Schild H; Dumrese T; Stevanović S; Rammensee HG
Eur J Biochem; 1997 Oct; 249(1):171-9. PubMed ID: 9363769
[TBL] [Abstract][Full Text] [Related]
14. Invariant chain transmembrane domain trimerization: a step in MHC class II assembly.
Dixon AM; Stanley BJ; Matthews EE; Dawson JP; Engelman DM
Biochemistry; 2006 Apr; 45(16):5228-34. PubMed ID: 16618111
[TBL] [Abstract][Full Text] [Related]
15. Interaction of MHC class II molecules with the invariant chain: role of the invariant chain (81-90) region.
Stumptner P; Benaroch P
EMBO J; 1997 Oct; 16(19):5807-18. PubMed ID: 9312039
[TBL] [Abstract][Full Text] [Related]
16. Molecular modeling and design of invariant chain peptides with altered dissociation kinetics from class II MHC.
Liang MN; Lee C; Xia Y; McConnell HM
Biochemistry; 1996 Nov; 35(47):14734-42. PubMed ID: 8942634
[TBL] [Abstract][Full Text] [Related]
17. Action of brain cathepsin B, cathepsin D, and high-molecular-weight aspartic proteinase on angiotensins I and II.
Azaryan A; Barkhudaryan N; Galoyan A; Lajtha A
Neurochem Res; 1985 Nov; 10(11):1525-32. PubMed ID: 3911093
[TBL] [Abstract][Full Text] [Related]
18. Human B lymphoblastoid cells contain distinct patterns of cathepsin activity in endocytic compartments and regulate MHC class II transport in a cathepsin S-independent manner.
Lautwein A; Kraus M; Reich M; Burster T; Brandenburg J; Overkleeft HS; Schwarz G; Kammer W; Weber E; Kalbacher H; Nordheim A; Driessen C
J Leukoc Biol; 2004 May; 75(5):844-55. PubMed ID: 14966190
[TBL] [Abstract][Full Text] [Related]
19. Immunological significances of invariant chain from the aspect of its structural homology with the cystatin family.
Katunuma N; Kakegawa H; Matsunaga Y; Saibara T
FEBS Lett; 1994 Aug; 349(2):265-9. PubMed ID: 8050579
[TBL] [Abstract][Full Text] [Related]
20. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading.
Riese RJ; Wolf PR; Brömme D; Natkin LR; Villadangos JA; Ploegh HL; Chapman HA
Immunity; 1996 Apr; 4(4):357-66. PubMed ID: 8612130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
